Debiopharm Invests in Diagnoplex to Push Colon Cancer MDx Through Clinical Trials
January 20, 2011
Debiopharm Invests in Diagnoplex to Push Colon Cancer MDx Through Clinical Trials
Diagnoplex received a boost toward commercializing its flagship PCR-based colon cancer blood test in the form of a "substantial" Series A financing extension by fellow Swiss biopharmaceutical conglomerate Debiopharm Group.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Immunexpress, Biocartis, Debiopharm to Further Develop Sepsis MDx
June 19, 2012 / GenomeWeb Daily News - Lumora-FIND Malaria Screening Test May be Tip of Iceberg in MDx Development Partnership
April 18, 2013 / PCR Insider - Seegene Licenses Multiplex Assay Technologies to BioMerieux for Food Safety Testing
April 15, 2013 / GenomeWeb Daily News - Dx Focus: Diagnovus Engauge-Cancer-DLBCL; Epigenomics Epi ProColon
February 21, 2013 / PCR Insider - Spinomix Nabs $3M in New Financing
January 9, 2013 / GenomeWeb Daily News